BMED vs WDNA: Holdings Overlap & Returns
Over the year to Nov 13, 2026, BMED returned +25.4% to WDNA's +43.3%; 23% of their weight is in the same names.
- Return gap
- +17.9 pts1 year to Nov 13, 2026: WDNA ahead, total return
- Fee gap
- 0.10 ptsA year: BMED 0.55%, WDNA 0.45%, per filings dated Nov 21, 2025 and Oct 28, 2026
- Overlap
- 23%Share of the two books held in common, holdings dated Nov 12, 2026 and Jun 30, 2026
- Net flow
- –Needs daily flows for both funds
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
BMED +25.4%, WDNA +43.3%: WDNA +17.9 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Cost to trade
Hypothetical. A $10,000 order in BMED costs about $11.50 one way and $23.00 in and out, at a median spread of 0.23%. The 0.23% spread is BMED’s 30-day median, from iShares (fund page).
Fees over time
Hypothetical. $10,000 in BMED for 10 years at 0.55% a year costs about $908 in fees and lost growth; WDNA at 0.45% would cost $746. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
58% of BMED's weight is in S&P 500 companies and 42% is outside the index. Holdings as of Nov 12, 2026.
26% of WDNA's weight is in S&P 500 companies and 74% is outside the index. Holdings as of Jun 30, 2026.
Key numbers
WDNA costs 0.10 points a year less; their one-year returns differ by 17.9 points.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +25.4% | +43.3% |
|---|---|---|
| Below its all-time high | 13.9%, high on Sep 2, 2021 | |
| What it tracks | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| Expense ratio | 0.55% | 0.45% |
| Net assets, BMED as of Nov 13, 2026 and WDNA as of Jun 30, 2026 | $15m | $2.7m |
| Holdings in common | 23% |
The numbers behind it
Net assets: $15m on Nov 13, 2026 for iShares Health Innovation Active ETF, and $2.7m on Jun 30, 2026 for WisdomTree BioRevolution Fund.
Holdings in common uses holdings dated Jun 30, 2026 and Nov 12, 2026.
What they share
By the books each fund has filed, BMED and WDNA hold 23% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 12, 2026.
half
23% in common
Held in common
Show all 12 holdings
| MODERNA | 5.52% | 4.14% |
| AMGEN INC | 2.57% | 1.54% |
| THERMO FISHER SCIENTIFIC | 4.33% | 1.52% |
| GILEAD SCIENCES | 5.80% | 1.51% |
| ROIVANT SCIENCES LTD | 1.42% | 1.73% |
| PFIZER | 1.46% | 1.34% |
| VERTEX PHARMACEUTICALS | 3.29% | 1.34% |
| NOVARTIS AG | 1.29% | 1.33% |
| JOHNSON & JOHNSON | 1.27% | 2.97% |
| ARGENX SE ADR | 1.87% | 0.94% |
| TEMPUS AI CLASS A | 0.91% | 2.28% |
| BIOGEN | 3.70% | 0.82% |
Only in BMED
Show all 8 holdings
| ABBVIE | 4.91% |
| EDWARDS LIFESCIENCES | 4.25% |
| METTLER-TOLEDO INTERNATIONAL INC | 3.61% |
| IQVIA HOLDINGS INC | 3.58% |
| ROCHE PS PAR AG | 2.85% |
| AGILENT TECHNOLOGIES INC | 2.34% |
| NEUROCRINE BIOSCIENCES | 2.31% |
| WATERS CORP | 2.25% |
Only in WDNA
Show all 8 holdings
| TWIST BIOSCIENCE CORP | 5.95% |
| ELI LILLY & COMPANY | 4.08% |
| UNITED THERAPEUTICS CORP | 2.45% |
| NATERA INC | 2.32% |
| IMMUNOME INC | 2.26% |
| STRUCTURE THERAPEUTICS INC | 2.12% |
| STOKE THERAPEUTICS INC | 2.09% |
| BEAM THERAPEUTICS INC | 2.09% |
Side by side
Open the table
| Fund | iShares Health Innovation Active ETF · Holds 55 stocks in healthcare innovation and GLP-1, 58% of its weight in S&P 500 companies | WisdomTree BioRevolution Fund · Holds 80 stocks in healthcare innovation and GLP-1, 26% of its weight in S&P 500 companies |
| Issuer | iShares | WisdomTree |
| Theme | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| In the S&P 500 | 58.2% | 25.9% |
| Active share vs the S&P 500 | 95.6% | 95.3% |
| In the Nasdaq-100 | 13.8% | 5.2% |
| Holdings | 55 | 80 |
| Top ten, share of the fund | 44.1% | 30.7% |
| Expense ratio | 0.55% | 0.45% |
| Fee for the differing part | 0.58% | 0.47% |
| Total return, 1 year | +25.4% | +43.3% |
| vs its benchmark | not measured | not measured |
| Below its high | −2.7% | −13.9% |
| Net assets, BMED as of Nov 13, 2026 and WDNA as of Jun 30, 2026 | $15m | $2.7m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | +12.9% | +6.8% |
|---|---|---|
| 6 months | +33.6% | +30.6% |
| 1 year | +25.4% | +43.3% |
| 3 years | +68.1% | +62.5% |
| Since launch (Not the same days: BMED Oct 2020 · WDNA Jun 2021) | +42.8% | −3.7% |
About BMED
By weight, 58% of BMED's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 96%. The top ten holdings are 44% of the fund across 55 positions, as published by its issuer for Nov 12, 2026.
More
Over the year to Nov 13, 2026 the fund returned +25.4% with distributions reinvested.
About WDNA
By weight, 26% of WDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 95%. The top ten holdings are 31% of the fund across 80 positions, as filed for Jun 30, 2026.
More
Over the year to Nov 13, 2026 the fund returned +43.3% with distributions reinvested. It sits 13.9% below its all-time high of Sep 2, 2021.
23% of the two portfolios are the same securities at the same weight.
Questions people ask
Do BMED and WDNA hold the same stocks?
By their latest filings, 23% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, BMED against WDNA, data as of Nov 13, 2026. https://etfiq.com/compare/themes/bmed-vs-wdna
ETFIQ. (Nov 13, 2026). BMED against WDNA. Retrieved from https://etfiq.com/compare/themes/bmed-vs-wdna
[BMED against WDNA (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/bmed-vs-wdna)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.